Official announcements
Safety warnings
|
Blood & Tissue
|
06/08/2013
The provinces of Bologna and Modena were added to the already known risk areas.
Recall
|
Medicines
|
06/08/2013
B. Braun Austria Ges.m.b.H. has informed its supplied customers in a letter dated August 5, 2013, that a customer complaint has informed the marketing authorization holder about a leaking Ecoflac plus infusion container in batch 13103411. Since it…
Safety warnings
|
messages in brief
|
26/07/2013
Metoclopramide-containing medicinal products are approved in a number of Member States in various indications, including nausea and vomiting (for example, after chemotherapy or radiotherapy, surgery, or for migraine) and gastrointestinal motility…
messages in brief
|
25/07/2013
Please note the new account number of the Federal Office for Safety in Health Care (BASG) / AGES Medizinmarktaufsicht: BAWAG P.S.K. AG IBAN: AT59 6000 0000 9605 1496 BIC: OPSKATWW DVR: 2112611 Inquiries: E-mail: qmgt@ages.at
Safety warnings
|
Blood & Tissue
|
17/07/2013
First confirmed infection recorded in Greece, Attiki.
Safety warnings
|
Blood & Tissue
|
12/07/2013
Number of cases increased to 201 ill persons by July 4, 2013 and thus now epidemic.
Recall
|
Medicines
|
11/07/2013
The marketing authorization holder informed its supplied customers in a letter dated July 9, 2013, that in the course of quality assurance measures it was determined that in batch 1200758 isolated ampoules with yellowish discolored contents and thus…
Replacement
|
Medicines
|
04/07/2013
The distribution partner "sanofi-aventis GmbH" informed its supplied customers in a letter dated 04.07.2013 that the retained samples of the above batch showed deviations. After a storage time of 26 months, aggregates above the permissible limit of…
Safety warnings
|
messages in brief
|
28/06/2013
Ergot derivatives (various preparations)
Recall
|
Veterinary Medicines
|
28/06/2013
The marketing authorization holder informed its supplied customers in a letter dated 17.06.2013 that a decrease in gentamicin content was observed in a batch of Soligental after 14 months of use (85.1%; specification: 95-105%) and that all batches of…